Fig. 7

Lung cancer PDO-based high-throughput screening (HTS) and cancer organoid-based diagnosis reactivity prediction (CODRP) index analysis to brigatinib. DRC-based drug response analysis using ALK-positive (A) and ALK-negative (B) patient-derived organoids to brigatinib. (C) Comparative analysis of drug response based on the AUC and CODRP indices for brigatinib; The CODRP index is calculated as a Z-score value based on different mean and standard deviation (SD) values of brigatinib for individual PDO, considering the AUC index, cancer stage, and PDO growth rate through multiple linear regression (Mean, SD, and sample number of brigatinib: 0.71, 0.32, 17). In the conventional AUC index-based analysis for the brigatinib, the sensitivity was 80% and the specificity was 58.3%, but as a result of the CODRP index-based drug sensitivity analysis, the analysis performance improved to 100% sensitivity and 83.3% specificity. The cut-off value for classifying drug responses into sensitive and resistant groups to three ALK-targeted drugs is 0